Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized neostigmine strategy to reverse residual rocuronium-induced neuromuscular blockade
ChiCTR2100052809Phase 4Completed
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of neostigmine in neuromuscular block (NMB) (4 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Train-of-four stimulation ratio (TOFR). Started Dec 2020; status: completed.
02
Drugs
neostigmine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR2100052809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052809.